Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

被引：8
|
作者：
Stein, Alexander
Binder, Mascha
Al-Batran, Salah-Eddin
Hinke, Axel
Waberer, Lisa
Goekkurt, Eray
Meyer, Tobias
Statovci, Donjete
Depenbusch, Reinhard
Riera-Knorrenschild, Jorge
Lorenzen, Sylvie
Ettrich, Thomas Jens
Doerfel, Steffen
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Hamburg Eppendorf, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] UCT Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[4] CCRC, Dusseldorf, Germany
[5] Krankenhaus Nordwest IKF, Frankfurt, Germany
[6] Univ Canc Ctr Hamburg, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] AIO Studien GmbH, Berlin, Germany
[8] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[9] Universitatsklinikum, Giessen, Germany
[10] Tech Univ Munich, Dept Internal Med Hematol Med Oncol 3, Klin Rechts Isar, Munich, Germany
[11] Ulm Univ Hosp, Ulm, Germany
[12] Onkozentrum Dresden, Dresden, Germany
[13] Hamatologisch Onkolog Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3561
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3561
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [32] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, J. A.
    Stuart, K.
    Zhu, A.
    Fuchs, C.
    Bhargava, P.
    Earle, C.
    Blaszkowsky, L.
    Lawrence, C.
    Battu, S.
    Ryan, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [33] Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
    Pauligk, C.
    Goetze, T. O.
    Thuss-Patience, P. C.
    Riera-Knorrenschild, J.
    Goekkurt, E.
    Ettrich, T. J.
    Pink, D.
    Lindig, U.
    Luley, K. B.
    Dechow, T.
    Bitzer, M.
    Angermeier, S.
    Homann, N.
    Kullmann, F.
    Schuch, G.
    Bolling, C.
    Junge, S.
    Hofheinz, R. D.
    Lorenzen, S.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2020, 31 : S908 - S908
  • [34] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).
    Abubakr, Y.
    Eng, C.
    Wong, L.
    Pautret, V.
    Scheithauer, W.
    Maurel, J.
    Kroening, H.
    Lutz, M.
    Zubel, A.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [35] A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results
    Cunningham, D.
    Wong, R. P.
    D'haens, G.
    Douillard, J.
    Robertson, J.
    Saunders, O.
    Stone, M.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205
    von Wichert, G.
    Hoehler, T.
    Schimanski, C. C.
    Moehler, M. H.
    Hofheinz, R.
    Kanzler, S.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hacker, U. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
    Hong, YS
    Song, SY
    Lee, SI
    Chung, HC
    Choi, SH
    Noh, SH
    Park, JN
    Han, JY
    Kang, JH
    Lee, KS
    Cho, JY
    ANNALS OF ONCOLOGY, 2004, 15 (09) : 1344 - 1347
  • [38] LONG TERM RESULTS OF A MULTICENTRE PHASE II TRIAL ASSESSING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS ACCORDING TO KRAS STATUS
    Samalin, E.
    Francoise, D.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 23 - 23
  • [39] Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Sobrero, A. F.
    Bennicelli, E.
    Pessino, A.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] PHASE II STUDY OF S-1 COMBINED WITH IRINOTECAN AND OXALIPLATIN (TIROX) IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Hong, Y. S.
    Kim, S. Y.
    Park, J. W.
    Lim, S.
    Choi, H. S.
    Jeong, S. Y.
    Kim, D. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
12345